Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE research at ECCMID Astellas reported today that the efficacy and basic safety data of the isavuconazole invasive aspergillosis research were presented in the European Congress of Clinical Microbiology and Infectious Illnesses in Barcelona, Spain. Previously announced topline data showed that the randomized, double-blind SECURE research met the primary goal of demonstrating non-inferiority of isavuconazole versus voriconazole for the principal treatment of invasive fungal disease caused by Aspergillus species or specific additional filamentous fungi. Baseline features of the severely ill patient population signed up for this trial were balanced between treatment groupings and had been reflective of patients at risk for invasive fungal disease cytoxan breast cancer .
Furthermore, astaxanthin does not oxidize after removing free of charge radicals, allowing it to keep working. It is also able to remove a multitude of different free radicals simultaneously, rather than being able to remove only 1 at the same time or being specifically attuned to a certain class of free radicals the way most antioxidants are. Like many antioxidants, astaxanthin is a potent anti-inflammatory also. This appears to underlie many of its health advantages, since chronic swelling has been associated with a multitude of chronic diseases including many cancers, heart disease, Alzheimer’s disease and diabetes. Yet once again, astaxanthin appears to be effective at reducing chronic swelling remarkably. It is frequently used as a remedy for joint pain from arthritis now, carpal tunnel syndrome and exercise-related conditions.